Welcome to our dedicated page for Surrozen Common news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen Common stock.
Surrozen, Inc. (Nasdaq: SRZN) is a clinical-stage biotechnology firm based in South San Francisco, focused on pioneering regenerative medicine. The company leverages its proprietary technologies to selectively activate the Wnt signaling pathway, a crucial mediator of tissue repair and regeneration. Founded by esteemed scientists from Stanford University, Surrozen aims to unlock the body's self-renewal capabilities through innovative therapeutic approaches.
The company's product pipeline includes several promising candidates:
- SZN-043: Surrozen's lead candidate, SZN-043, uses the company's SWEETS™ technology to treat severe liver diseases, specifically alcohol-associated hepatitis. Following a successful Phase 1a trial that demonstrated safety and target engagement, the company has initiated a Phase 1b clinical trial, with proof-of-concept data anticipated by mid-2025.
- SZN-413: Developed for retinal vascular-associated diseases, SZN-413 leverages Surrozen's SWAP™ technology. Preclinical models have shown that SZN-413 can stimulate Wnt signaling in the eye, potentially inducing normal retinal vessel regrowth. The company has partnered with Boehringer Ingelheim for further research and development, with milestone payments potentially reaching $587.0 million.
Surrozen's strategic direction also includes a strong focus on severe eye diseases and potential applications in other tissues such as the lung and kidney. The company recently published data indicating the potential of Wnt mimetic technologies to treat idiopathic pulmonary fibrosis.
With $43.4 million in cash, cash equivalents, and marketable securities as of September 2023, Surrozen is well-positioned financially to continue its innovative research and clinical trials. The company emphasizes transparency and forward-looking statements, promising continued updates as they advance their clinical programs.
For more details about career opportunities and their latest news, please visit Surrozen's official website.
Surrozen, Inc. (Nasdaq: SRZN), a biotech firm focusing on Wnt pathway therapeutics, appointed Eric Bjerkholt to its Board of Directors. Bjerkholt, who has extensive experience in biotechnology, is currently the CFO of Chinook Therapeutics and previously served as CFO of Aimmune Therapeutics, leading its $2.6 billion acquisition by Nestlé Health Science. Surrozen's Board now consists of nine members with diverse expertise in the field. CEO Craig Parker expressed confidence in Bjerkholt's insights and strategic acumen, especially as the company aims to develop technologies addressing significant medical needs.
Surrozen, Inc. (SRZN) announced key developments in its clinical pipeline, enrolling the first patient in the Phase 1a trial of SZN-043 for chronic liver disease, with data expected by the end of 2023. The company plans to initiate a Phase 1b trial for severe alcoholic hepatitis in 2024, anticipating proof-of-concept data in the latter half of 2024. SZN-1326's Phase 1a trial in healthy volunteers is set to resume by mid-2023, with potential ulcerative colitis data expected in 2024. Surrozen's restructuring initiatives have extended its cash runway into late 2024. The company's financial position includes approximately $75.8 million in cash, with R&D expenses reduced by 15% in 2023.
Surrozen, Inc. (Nasdaq: SRZN) will report its Q4 and full year 2022 financial results on March 22, 2023, after the U.S. markets close. The company will also provide a corporate and pipeline progress update during a live audio webcast at 4:30 PM ET. Interested participants can access the webcast via the Investor website. Surrozen is a clinical-stage biotechnology firm focused on developing drug candidates that selectively modulate the Wnt pathway, targeting conditions like inflammatory bowel disease, severe liver issues, and eye diseases.
Surrozen, a clinical-stage biotechnology company, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 7:30 a.m. Pacific time. The presentation will focus on their innovative therapies targeting the Wnt pathway for tissue repair and regeneration. A live audio webcast will be available on Surrozen's Investor Relations website. Surrozen aims to address diseases like inflammatory bowel disease and certain neurological disorders through its targeted therapies.
Surrozen, Inc. (Nasdaq: SRZN) reported Q3 2022 financial results, with cash reserves at $78.4 million, down from $92.7 million in Q2 2022. The net loss narrowed to $13.4 million from $14.0 million a year prior. Enrollment in the SZN-1326 Phase 1 trial was paused due to adverse liver events, while SZN-043 is ongoing with mild liver transaminase elevations observed. Surrozen partnered with Boehringer Ingelheim for SZN-413, receiving a $12.5 million upfront payment and potential future milestones of $586.5 million. Research expenses decreased to $8.6 million, while general administrative expenses rose to $5.0 million.
FAQ
What is the current stock price of Surrozen Common (SRZN)?
What is the market cap of Surrozen Common (SRZN)?
What is Surrozen, Inc.?
What is SZN-043?
Who are the founders of Surrozen?
What is SZN-413?
What is the Wnt signaling pathway?
How is Surrozen positioned financially?
What are the potential applications of Surrozen's technologies?
What recent achievements has Surrozen announced?
What should investors know about Surrozen's forward-looking statements?
How can one apply for a career at Surrozen?
